FDA Approves Lytenava for Wet AMD, Outlook Therapeutics Surges 12%

Outlook Therapeutics (OTLK) shares jumped 12% in pre-market trading after the FDA approved Lytenava (bevacizumab-vikg) for wet age-related macular degeneration. The decision arrived two days ahead of the July 29 target date, marking a major regulatory win for the company after a rocky approval path.

Lytenava is now the first and only FDA-approved ophthalmic formulation of bevacizumab developed specifically for wet AMD in the United States. The approval follows a December 2025 rejection, which required additional clinical evidence. Outlook appealed, and in May the FDA’s Office of New Drugs ruled existing data sufficient—clearing the way without further trials.

Analysts reacted swiftly. BTIG upgraded OTLK from Neutral to Buy with a $4.00 price target. The 12-month consensus target stands at $5.50, implying roughly 290% upside from Friday’s close of $1.41. The stock had already gained 6% on Friday ahead of the approval.

The approval underscores the FDA’s willingness to reconsider decisions when new arguments are presented, a dynamic that may signal a more flexible regulatory environment for specialty biotech firms. For Outlook, it transforms a long-shot appeal into a commercial opportunity with an approved product in a multi-billion-dollar market.

Investors will now watch for launch execution and potential partnerships. The wet AMD treatment landscape is competitive, but Lytenava’s first-in-class ophthalmic bevacizumab status gives Outlook a unique positioning in the U.S. market.